Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study

Human epidermal growth factor receptor 2 (HER2) is a well-developed therapeutic target in breast and gastric cancer (GC). However, the impact of HER2 on survival and benefit from fluorouracil-based adjuvant chemotherapy remains unclear in patients with GC. MATERIALS AND METHODS: This multicenter coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xianchun, Zhao, Lulu, Zhang, Nannan, Han, Weili, Liu, Kun, Yan, Junya, Chen, Ling, Pan, Yan, Li, Renlong, Li, Wenjiao, Zhang, Haohao, Li, Hongwei, Wang, Shibo, Gao, Xiaoliang, Niu, Penghui, Wang, Wanqing, Ji, Gang, Zhao, Qingchuan, Lu, Yuanyuan, Li, Zengshan, Shang, Lei, Liang, Han, Wu, Kaichun, Deng, Jingyu, Chen, Yingtai, Nie, Yongzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389606/
https://www.ncbi.nlm.nih.gov/pubmed/37037586
http://dx.doi.org/10.1097/JS9.0000000000000370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389606/
https://www.ncbi.nlm.nih.gov/pubmed/37037586
http://dx.doi.org/10.1097/JS9.0000000000000370

Ejemplares similares